- Cyclic compound capable of inhibiting programmed death receptor ligand 1, and uses thereof
-
The present invention proposes a cyclic compound capable of inhibiting a programmed death receptor ligand 1, and uses thereof, wherein the compound is a compound represented by a formula I, or a pharmaceutically acceptable salt, a hydrate, a solvate, a metabolite, a stereoisomer or a prodrug thereof, and R1, R2, R3 are defined in the specification. According to the present invention, the compoundcan be used as the small molecule PD-L1 inhibitor, and can be used for preparing drugs for treatment and/or prevention of tumors. The formula I is defined in the specification.
- -
-
Paragraph 0056-0060
(2018/09/08)
-
- THERAPEUTIC CYCLIC COMPOUNDS AS IMMUNOMODULATORS
-
The present invention relates to cyclic compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
- -
-
Page/Page column 42
(2016/09/26)
-
- Cyclic Peptidomimetic Compounds as Immunomodulators
-
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
- -
-
Paragraph 0129; 0130
(2015/03/16)
-
- CYCLIC PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS
-
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
- -
-
Page/Page column 19; 20
(2015/03/28)
-
- Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid
-
A synthetic reaction to produce [2-(2-aminoethoxy)ethoxy] acetic acid (AEEA) derivatives. This synthetic reaction does not require isolation and purification of intermediates. The AEEA derivatives can be used to synthesize high load polystyrene-polyethylene glycol-like resins having excellent swelling characteristics.
- -
-
-